公开(公告)号：WO2005039551A2

公开(公告)日：2005-05-06

申请号：PCT/US2004/027401

申请日：2004-08-23

Applicant: ABBOTT LABORATORIES ,  ROSENBERG, Jöerg ,  REINHOLD, Ulrich ,  LIEPOLD, Bernd ,  DERNDL, Gunther ,  BREITENBACH, Jörg ,  ALANI, Laman ,  GHOSH, Soumojeet

Inventor： ROSENBERG, Jöerg ,  REINHOLD, Ulrich ,  LIEPOLD, Bernd ,  DERNDL, Gunther ,  BREITENBACH, Jörg ,  ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K31/00

CPC classification number: A61K31/425 ,  A61K9/146 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2866

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 °C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract translation: 公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。 特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约50 C。 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。

公开(公告)号：EP1663183B1

公开(公告)日：2011-07-13

申请号：EP04816820.7

申请日：2004-08-23

Applicant: ABBOTT LABORATORIES

Inventor： ROSENBERG, Jöerg ,  REINHOLD, Ulrich ,  LIEPOLD, Bernd ,  DERNDL, Gunther ,  BREITENBACH, Jörg ,  ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K9/14 ,  A61K31/425 ,  A61K9/20

CPC classification number: A61K31/425 ,  A61K9/146 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2866

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 °C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

公开(公告)号：EP1663183B9

公开(公告)日：2012-06-13

申请号：EP04816820.7

申请日：2004-08-23

Applicant: ABBOTT LABORATORIES

Inventor： ROSENBERG, Jöerg ,  REINHOLD, Ulrich ,  LIEPOLD, Bernd ,  DERNDL, Gunther ,  BREITENBACH, Jörg ,  ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K9/14 ,  A61K31/425 ,  A61K9/20

CPC classification number: A61K31/425 ,  A61K9/146 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2866

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 °C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

公开(公告)号：EP1663183A2

公开(公告)日：2006-06-07

申请号：EP04816820.7

申请日：2004-08-23

Applicant: ABBOTT LABORATORIES

Inventor： ROSENBERG, Jöerg ,  REINHOLD, Ulrich ,  LIEPOLD, Bernd; ,  DERNDL, Gunther ,  BREITENBACH, Jörg ,  ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K31/00

CPC classification number: A61K31/425 ,  A61K9/146 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2866

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 °C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.